COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study

Basit Öğe Kaydı
dc.authoridKESKINKAYA, ZEYNEP/0000-0002-2982-3823
dc.authoridKAYA, OZGE/0000-0001-8062-1664
dc.authoridOGUZ KILIC, SEVILAY/0000-0003-3560-849X
dc.contributor.authorKaya, Ozge
dc.contributor.authorKeskinkaya, Zeynep
dc.contributor.authorMermutlu, Selda Isik
dc.contributor.authorKilic, Sevilay Oguz
dc.contributor.authorCakir, Haile
dc.date.accessioned2025-01-27T21:19:51Z
dc.date.available2025-01-27T21:19:51Z
dc.date.issued2023
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective: Psoriasis patients may have been affected by COVID-19 differently than the nor-mal population due to using different types of treatments, including immunosuppressive agents and biological therapies, the probability of lower effectiveness, and different side effects of the vaccines. This study aimed to evaluate the epidemiologic and clinical features of COVID-19 and the effect of the psoriasis treatment on it. Materials and Methods: Psoriasis patients followed up in our clinic between March 2020 and July 2022 were evaluated in terms of clinicodemographic characteristics, treatment methods, and COVID-19 vaccination status and compared regarding COVID-19 history. Results: A total of 110 patients (female:male ratio=1:1.2) with a mean age of 45.6 +/- 14.3 years were evaluated. Thirty patients (27.2%) developed COVID-19 during psoriasis treatment. Unvaccinated patients had COVID-19 (6/11, 55%) more frequently than vaccinated ones (24/99, 24%), but it was not statistically significant (p=0.067). Although patients who re-ceived biological therapy were also more frequently infected with SARS-CoV-2 than pa-tients who received other types of therapies (18/53 [34%] versus 12/57 [21%], respectively), the difference was again not statistically significant. A patient with hypertension using acitretin was hospitalized for pulmonary involvement because of COVID-19. No exacerba-tion of psoriasis was observed in patients who developed COVID-19, while psoriasis flares occurred following COVID-19 mRNA vaccination in two patients. Conclusion: Patients with psoriasis should get vaccinated against COVID-19, as vaccination prevents the disease and does not result in serious side effects. Although using biological agents for the treatment of psoriasis could be related to a higher risk of getting COVID-19, these agents do not increase the risk of severe COVID-19. Therefore, they may be beneficial in reducing the risk of both psoriasis exacerbations and severe COVID-19 due to the cy-tokine storm among patients using biological for psoriasis. However, large-scale and con-trolled studies are needed to support our conclusions.
dc.identifier.doi10.36519/idcm.2023.192
dc.identifier.endpage135
dc.identifier.issn2667-646X
dc.identifier.issue2
dc.identifier.pmid38633013
dc.identifier.startpage127
dc.identifier.trdizinid1183917
dc.identifier.urihttps://doi.org/10.36519/idcm.2023.192
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1183917
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28752
dc.identifier.volume5
dc.identifier.wosWOS:001138794000008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherDoc Design Informatics Co Ltd
dc.relation.ispartofInfectious Diseases and Clinical Microbiology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectanti-TNF
dc.subjectbiological drugs
dc.subjectCOVID-19
dc.subjectimmunosuppressive drugs
dc.subjectpsoriasis
dc.subjecttreatment
dc.titleCOVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu